1. Report Overview
1.1. Global Cancer Biologics Market Overview
1.2. Why You Should Read This Report
1.3. How This Report Delivers
1.4. Key Questions Answered by This Analytical Report
1.5. Who Is This Report For?
1.6. Methodology
1.6.1. Primary Research
1.6.2. Secondary Research
1.6.3. Market Evaluation & Forecasting Methodology
1.7. Frequently Asked Questions (FAQ)
1.8. Associated Visiongain Reports
1.9. About Visiongain
2. Introduction to the Cancer Biologics Market
2.1. Cancer Biologics Market Definition
2.2. Treatments used in Cancer Biologics Industry
2.2.1. Chemotherapy
2.2.2. Targeted Therapy
2.2.2.1. Monoclonal Antibodies
2.2.2.2. Small-Molecule Drugs
2.2.3. Immunotherapy
2.2.4. Hormonal Therapy
2.3. Cancer Biologics Industry by Indication
2.3.1. Breast Cancer
2.3.2. Cervical Cancer
2.3.3. Colon and Rectal Cancer
2.3.4. Gastric Cancer
2.3.5. Lung Cancer
2.3.6. Ovarian Cancer
2.3.7. Renal Cell Cancer
2.3.8. Melanoma
3. Cancer Biologics Market Overview
3.1. Global Oncology Spending Market Size, Market Analysis and Forecast, 2016-2031
3.2. Global and Regional Cancer Biologics Market, 2021-2031
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rising Cancer Prevalence Worldwide
3.3.1.2. Increasing Ageing Population in Developed as well as Developing Economies
3.3.2. Market Restraints/Challenges
3.3.2.1. Shortage of Skilled Workforce in the Biopharmaceutical Industry
3.3.2.2. High Cost Associated with Biopharmaceutical Drug Manufacturing
3.3.3. Opportunities
3.3.3.1. Increasing R&D Spending of Biopharmaceutical Companies
3.3.3.2. Future Perspective in Oncology Industry
3.4. Cancer Biologics Market: SWOT Analysis
3.5. Cancer Biologics Market: Porter’s Five Forces Model
3.5.1. Bargaining Power of Buyers
3.5.2. Bargaining Power of Suppliers
3.5.3. Threats of New Entrants
3.5.4. Threats of Substitutes
3.5.5. Competitive Rivalry
3.6. European Oncology Market Trends
3.7. Disease Prevalence and Incidence in Europe
3.7.1. Germany Cancer Incidence and Mortality
3.7.2. UK Cancer Incidence and Mortality
3.7.3. France Cancer Incidence and Mortality
3.7.4. Italy Cancer Incidence and Mortality
3.7.5. Spain Cancer Incidence and Mortality
3.7.6. Portugal Cancer Incidence and Mortality
3.7.7. Poland Cancer Incidence and Mortality
3.7.8. Hungary Cancer Incidence and Mortality
3.7.9. Czech Republic Cancer Incidence and Mortality
3.7.10. Slovakia Cancer Incidence and Mortality
3.7.11. Slovenia Cancer Incidence and Mortality
3.7.12. Romania Cancer Incidence and Mortality
3.7.13. Bulgaria Cancer Incidence and Mortality
3.7.14. Croatia Cancer Incidence and Mortality
3.7.15. Serbia Cancer Incidence and Mortality
3.8. Prescription Distribution of Bevacizumab and Trastuzumab
3.8.1. Prescription Distribution of Bevacizumab
3.8.1.1. Metastatic Colorectal Cancer
3.8.1.2. First-Line Non-Squamous Non–Small Cell Lung Cancer
3.8.1.3. Recurrent Glioblastoma
3.8.1.4. Metastatic Renal Cell Carcinoma
3.8.1.5. Persistent, Recurrent, Or Metastatic Cervical Cancer
3.8.1.6. Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
3.8.1.7. Hepatocellular Carcinoma
3.8.2. Prescription Distribution of Trastuzumab
3.8.2.1. Adjuvant Breast Cancer
3.8.2.2. Metastatic Breast Cancer
3.8.2.3. Metastatic Gastric Cancer
3.9. EMA Approval, Loss of Exclusivity and Introduction of Biosimilars Impact Analysis
3.10. Patient drop-out rate
3.11. Oncologist Perceptions on Biosimilars
3.12. Barriers to Biologic Treatments and Expected Impact of Cheaper Options on the Market
3.13. Biosimilars and R&D Biologics in Development
4. Global Cancer Biologics Market Analysis and Forecast 2021-2031, by Treatment Type
4.1. Chemotherapy Market Size
4.1.1. Side Effects of Chemotherapy
4.1.2. Cancer Biologics Market Outlook for Chemotherapy: Recovery Scenarios (V, U, L, W)
4.2. Targeted Therapy Market Size
4.2.1. Examples of Targeted Therapies
4.2.2. Targeted Therapies Approved for Specific Types of Cancer
4.2.3. Cancer Biologics Market Outlook for Targeted Therapy: Recovery Scenarios (V, U, L, W)
4.2.4. Tyrosine kinase inhibitors (small molecules) / mTOR, BRAF, etc. receptor targeted agents
4.2.5. Monoclonal antibodies / mAbs (VEGF, HER, DP1, etc. receptor targeted agents)
4.2.6. Antibody-drug conjugates – with mAbs or with a small molecule
4.3. Immunotherapy Market Size
4.3.1. What Does Immunotherapy Treat?
4.3.2. Types of Immunotherapy
4.3.3. Cancer Biologics Market Outlook for Immunotherapy: Recovery Scenarios (V, U, L, W)
4.4. Hormonal Therapy Market Size
4.4.1. Hormone Therapy for Breast Cancer
4.4.2. Hormone Therapy Drugs for Breast Cancer
4.4.3. Breast Cancer and Tamoxifen
4.4.4. Cancer Biologics Market Outlook for Hormonal Therapy: Recovery Scenarios (V, U, L, W)
4.5. Other Treatments Market Size
4.5.1. Are there Vaccines that Prevent Cancer?
4.5.2. Cancer Biologics Market Outlook for Other Treatments: Recovery Scenarios (V, U, L, W)
5. Global Cancer Biologics Market Analysis and Forecast 2021-2031, by Indication
5.1. Breast Cancer Market Size
5.1.1. Node Preservation Reduces Lymphedema Cases
5.1.2. Genomic Testing Minimizes Chemotherapy Exposure
5.1.3. Oral Option for Targeted Therapy
5.1.4. Breast Cancer Statistics, 2020
5.1.5. Cancer Biologics Market Outlook for Breast Cancer: Recovery Scenarios (V, U, L, W)
5.2. Cervical Cancer Market Size
5.2.1. Cancer Biologics Market Outlook for Cervical Cancer: Recovery Scenarios (V, U, L, W)
5.3. Colon and Rectal Cancer Market Size
5.3.1. Drugs Approved for Colon Cancer
5.3.2. Drugs Combinations Used in Colon Cancer
5.3.3. Drugs Approved for Rectal Cancer
5.3.4. Drugs Combinations Used in Rectal Cancer
5.3.5. Cancer Biologics Market Outlook for Colon and Rectal Cancer: Recovery Scenarios (V, U, L, W)
5.4. Gastric Cancer Market Size
5.4.1. Drugs Approved for Gastric Cancer
5.4.2. Drugs Combinations Used in Gastric Cancer
5.4.3. Drugs Approved for Gastroenteropancreatic Neuroendocrine Tumors
5.4.4. Cancer Biologics Market Outlook for Gastric Cancer: Recovery Scenarios (V, U, L, W)
5.5. Lung Cancer Market Size
5.5.1. Drugs Approved for Non-Small Cell Lung Cancer
5.5.2. Drug Combinations Used to Treat Non-Small Cell Lung Cancer
5.5.3. Drugs Approved for Small Cell Lung Cancer
5.5.4. Cancer Biologics Market Outlook for Lung Cancer: Recovery Scenarios (V, U, L, W)
5.6. Ovarian Cancer Market Size
5.6.1. Available Treatments for Ovarian Cancer
5.6.2. What New Treatment Options are Under Development?
5.6.3. Cancer Biologics Market Outlook for Ovarian Cancer: Recovery Scenarios (V, U, L, W)
5.7. Renal Cell Cancer Market Size
5.7.1. Cancer Biologics Market Outlook for Renal Cell Cancer: Recovery Scenarios (V, U, L, W)
5.8. Melanoma Market Size
5.8.1. Drugs Approved for Melanoma
5.8.2. Cancer Biologics Market Outlook for Melanoma: Recovery Scenarios (V, U, L, W)
5.9. Other Indications Market Size
5.9.1. Cancer Biologics Market Outlook for Other Indications: Recovery Scenarios (V, U, L, W)
6. Global Cancer Biologics Market Analysis and Forecast 2021-2031, by Biologic Drugs
6.1. Bevacizumab Market Size
6.1.1. Bevacizumab Similar Biologic Launched in India
6.1.2. Cancer Biologics Market Outlook for Bevacizumab: Recovery Scenarios (V, U, L, W)
6.2. Trastuzumab Market Size
6.2.1. Cancer Biologics Market Outlook for Trastuzumab: Recovery Scenarios (V, U, L, W)
6.3. Trastuzumab emtansine Market Size
6.3.1. Cancer Biologics Market Outlook for Trastuzumab emtansine: Recovery Scenarios (V, U, L, W)
6.4. Pertuzumab Market Size
6.4.1. FDA Accepted Roche’s Biologics License Application
6.4.2. Cancer Biologics Market Outlook for Pertuzumab: Recovery Scenarios (V, U, L, W)
6.5. Rituximab Market Size
6.5.1. Cancer Biologics Market Outlook for Rituximab: Recovery Scenarios (V, U, L, W)
6.6. Cetuximab Market Size
6.6.1. Cancer Biologics Market Outlook for Cetuximab: Recovery Scenarios (V, U, L, W)
6.7. Panitumumab Market Size
6.7.1. Cancer Biologics Market Outlook for Panitumumab: Recovery Scenarios (V, U, L, W)
6.8. Ramucirumab Market Size
6.8.1. Cancer Biologics Market Outlook for Ramucirumab: Recovery Scenarios (V, U, L, W)
6.9. Necitumumab Market Size
6.9.1. Role of Necitumumab in the Treatment of Non–Small Cell Lung Cancer (NSCLC)?
6.9.2. Cancer Biologics Market Outlook for Necitumumab: Recovery Scenarios (V, U, L, W)
6.10. Pembrolizumab Market Size
6.10.1. What Pembrolizumab Is Used For:
6.10.2. Cancer Biologics Market Outlook for Pembrolizumab: Recovery Scenarios (V, U, L, W)
6.11. Atezolizumab Market Size
6.11.1. Atezolizumab Drug Used in below Indiactions
6.11.2. Cancer Biologics Market Outlook for Atezolizumab: Recovery Scenarios (V, U, L, W)
6.12. Durvalumab Market Size
6.12.1. FDA Approved Durvalumab for Extensive-Stage Small Cell Lung Cancer
6.12.2. Cancer Biologics Market Outlook for Durvalumab: Recovery Scenarios (V, U, L, W)
6.13. Nivolumab Market Size
6.13.1. FDA to Review Additional GI Cancer Indications for Nivolumab
6.13.2. Cancer Biologics Market Outlook for Nivolumab: Recovery Scenarios (V, U, L, W)
6.14. Ipilimumab Market Size
6.14.1. Cancer Biologics Market Outlook for Ipilimumab: Recovery Scenarios (V, U, L, W)
7. Global Cancer Biologics Market Analysis and Forecast 2021-2031, by End User
7.1. Hospitals Market Size
7.1.1. Cancer Biologics Market Outlook for Hospitals: Recovery Scenarios (V, U, L, W)
7.2. Specialty Clinics Market Size
7.2.1. Cancer Biologics Market Outlook for Specialty Clinics: Recovery Scenarios (V, U, L, W)
7.3. Cancer and Radiation Therapy Centers Market Size
7.3.1. How is the Cancer Research Institute Involved in the Development of Immunotherapy?
7.3.2. Cancer Biologics Market Outlook for Cancer and Radiation Therapy Centers: Recovery Scenarios (V, U, L, W)
8. Europe Cancer Biologics Market Analysis and Forecast, 2021-2031
8.1. Europe Cancer Biologics Market Size
8.1.1. Europe Cancer Biologics Market Outlook: Recovery Scenarios (V, U, L, W)
8.2. UK Cancer Biologics Market Size
8.3. Germany Cancer Biologics Market Size
8.4. France Cancer Biologics Market Size
8.5. Italy Cancer Biologics Market Size
8.6. Spain Cancer Biologics Market Size
8.7. Portugal Cancer Biologics Market Size
8.8. Poland Cancer Biologics Market Size
8.9. Hungary Cancer Biologics Market Size
8.10. Czech Republic Cancer Biologics Market Size
8.11. Slovakia Cancer Biologics Market Size
8.12. Slovenia Cancer Biologics Market Size
8.13. Romania Cancer Biologics Market Size
8.14. Bulgaria Cancer Biologics Market Size
8.15. Croatia Cancer Biologics Market Size
8.16. Baltic States Cancer Biologics Market Size
8.17. Serbia Cancer Biologics Market Size
8.18. Rest of Europe Cancer Biologics Market Size
9. Company Profiles
9.1. AbbVie Inc.
9.1.1. AbbVie Inc. Snapshot
9.1.2. Company Overview
9.1.3. Product Offerings
9.1.4. AbbVie Inc.: Recent Initiatives, 2017 – 2020
9.1.5. Financial Performance (2015 – 2019)
9.1.5.1. Net Revenue (2015 – 2019)
9.1.5.2. Gross Profit (2015 – 2019)
9.1.5.3. Geographical Revenue, 2019
9.2. F.Hoffman La Roche
9.2.1. F.Hoffman La Roche Snapshot
9.2.2. Company Overview
9.2.3. Product Offerings
9.2.4. F.Hoffman La Roche: Recent Initiatives, 2017 – 2020
9.2.5. Financial Performance (2015 – 2019)
9.2.5.1. Net Revenue (2015 – 2019)
9.2.5.2. Gross Profit (2015 – 2019)
9.2.5.3. Geographical Revenue, 2019
9.3. GlaxoSmithKline
9.3.1. GlaxoSmithKline Snapshot
9.3.2. Company Overview
9.3.3. Product Offerings
9.3.4. GlaxoSmithKline: Recent Initiatives, 2017 – 2020
9.3.5. Financial Performance (2015 – 2019)
9.3.5.1. Net Revenue (2015 – 2019)
9.3.5.2. Gross Profit (2015 – 2019)
9.3.5.3. Geographical Revenue, 2019
9.4. Eli Lilly and Company
9.4.1. Eli Lilly and Company Snapshot
9.4.2. Company Overview
9.4.3. Product Offerings
9.4.4. Eli Lilly and Company: Recent Initiatives, 2017 – 2020
9.4.5. Financial Performance (2015 – 2019)
9.4.5.1. Net Revenue (2015 – 2019)
9.4.5.2. Gross Profit (2015 – 2019)
9.4.5.3. Geographical Revenue, 2019
9.5. Amgen
9.5.1. Amgen Snapshot
9.5.2. Company Overview
9.5.3. Product Offerings
9.5.4. Amgen: Recent Initiatives, 2017 – 2020
9.5.5. Financial Performance (2015 – 2019)
9.5.5.1. Net Revenue (2015 – 2019)
9.5.5.2. Gross Profit (2015 – 2019)
9.5.5.3. Geographical Revenue, 2019
9.6. Johnson & Johnson
9.6.1. Johnson & Johnson Snapshot
9.6.2. Company Overview
9.6.3. Product Offerings
9.6.4. Johnson & Johnson: Recent Initiatives, 2017 – 2020
9.6.5. Financial Performance (2015 – 2019)
9.6.5.1. Net Revenue (2015 – 2019)
9.6.5.2. Gross Profit (2015 – 2019)
9.6.5.3. Geographical Revenue, 2019
9.7. Merck & Co.
9.7.1. Merck & Co. Snapshot
9.7.2. Company Overview
9.7.3. Product Offerings
9.7.4. Merck & Co.: Recent Initiatives, 2017 – 2020
9.7.5. Financial Performance (2015 – 2019)
9.7.5.1. Net Revenue (2015 – 2019)
9.7.5.2. Gross Profit (2015 – 2019)
9.7.5.3. Geographical Revenue, 2019
9.8. Pfizer
9.8.1. Pfizer Snapshot
9.8.2. Company Overview
9.8.3. Product Offerings
9.8.4. Pfizer: Recent Initiatives, 2017 – 2020
9.8.5. Financial Performance (2015 – 2019)
9.8.5.1. Net Revenue (2015 – 2019)
9.8.5.2. Gross Profit (2015 – 2019)
9.8.5.3. Geographical Revenue, 2019
9.9. Other Notable Players
9.10. List of Companies Mentioned in this Report
10. Conclusion
10.1. Concluding Remarks
11. Glossary
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/